Jordan Christensen
@thebigjc
Husband, Dad to Simon, Vegan, SVP Tech @RecursionPharma. Formerly @ecobee, @wattpad, @kobo, @chaptersindigo, @blastradius. He/Him
You might like
A new report from @McKinsey focuses on the need for an integrated R&D tech stack to overcome ongoing inefficiencies in drug discovery & development. ▪️ Although @US_FDA approvals for novel therapeutics reached their second-highest levels in 30 years, the report notes, pharma’s…
We are excited to share today that two of our @RecursionPharma oncology programs have received regulatory approval to advance into clinical trials! Both of these programs are a testament to the precision design capabilities of the RecursionOS which allows us to create novel,…
Determining the best AI tools and investing in culture are key HR themes for 2025, Chief People & Impact Officer Erica Fox told @pavsmo of @FastCompany. 🔹 Erica was one of 15 HR leaders interviewed about her 2025 predictions for the future of work. Her takeaways: ▪️ While AI…
Check out @RecursionPharma 's latest paper that just got published in Nature Communications! 🎉 We introduce MolE, a new foundation model for chemistry. Paper (open access): rdcu.be/dZWa9 Blog: lnkd.in/ebGYAcqr 🧵 Thread
Continuing with our contributions to open science here at @RecursionPharma!
🚀Presenting at the NVIDIA AI Summit in Japan, @RecursionChris announced the release of our OpenPhenom-S/16 foundation model in @googlecloud's Vertex AI Model Garden & anticipated release on @NVIDIA’s platform. This non-commercial publicly available foundation model built on…
Thrilled to announce the first patient dosed in our Phase 2 trial of REC-3964 – a potential first-in-class, oral, non-antibiotic small molecule for the treatment of recurrent C. diff. infection and the first new chemical entity developed from the RecursionOS. There’s a major…
Recursion has built a lot of our software stack on Google Cloud over the years. This partnership cements that path as our future, and will enable us to continue to drive towards out mission.
Announcing today at @HLTHEVENT, we have made @Google our preferred #AI cloud partner as we scale our industry-leading dataset into the next generation. We’ll be able to: scale beyond our existing GPU footprint to quickly iterate on our ML models; query our >50 petabyte dataset at…
Announcing today at @HLTHEVENT, we have made @Google our preferred #AI cloud partner as we scale our industry-leading dataset into the next generation. We’ll be able to: scale beyond our existing GPU footprint to quickly iterate on our ML models; query our >50 petabyte dataset at…
Fantastic work and congratulations to the team @exscientiaAI! The collaboration with @sanofi is delivering on all cylinders! Impressive stuff! Pair that with the $30M map option we announced a few weeks ago from Roche/Genentech @RecursionPharma and I hope people can see some of…
We’re delighted to announce that we’ve achieved milestones for two programmes in our @sanofi collaboration, for which we’ll receive an aggregate of $15 million and are eligible for over $600 million in additional milestone payments. Learn more: investors.exscientia.ai/press-releases… $EXAI
🎉 Congratulations to Marissa Saunders, PhD, Senior Director of Data Science, who won the Data Innovator Award at the @WomenTechCncl's Women Tech Awards last night! 🎉 Marissa leads teams at the interface of deep learning & drug discovery who are designing & arranging data…
“This small molecule & novel target came out from essentially a Google-search equivalent, from this giant map of biology that we’ve already built.” New story from @ccheddarberk @CNBC on REC-1245 which progressed from target ID to IND in < 18 months. cnbc.com/2024/10/02/rec…
AI visionary @Yoshua_Bengio - Turing Award-winner, CS professor at @UMontreal & our scientific advisor - discussed the role of #AI in drug discovery w/ @bmabey & @bertonearnshaw. The takeaway: “We are on the trajectory to build the tools to do as well as human scientists or…
Announcing positive Phase 2 topline results for our first-in-disease treatment for cerebral cavernous malformation (#CCM) – the #AI drug discovery that launched our company. REC-994 met its primary endpoint of safety & tolerability & showed promising MRI-based secondary efficacy…
[1 of 7] Data is the differentiator. Today, we’re kicking off a series called Data Deep Dive – sharing how we collect, model & analyze #data in order to solve challenging biological problems and transform drug discovery. 🧵#datadeepdive
![RecursionPharma's tweet image. [1 of 7] Data is the differentiator. Today, we’re kicking off a series called Data Deep Dive – sharing how we collect, model &amp; analyze #data in order to solve challenging biological problems and transform drug discovery. 🧵#datadeepdive](https://pbs.twimg.com/media/GVmCs0vWsAAK7fk.jpg)
In a new episode of @nvidia's #AI Podcast, @RecursionChris talks to @noahkravitz about Recursion’s journey from an idea he began exploring at @UUtah to a leading #TechBio company with one of the largest proprietary datasets in the industry & #pharma’s fastest supercomputer. Learn…
"It's our goal to prove that this kind of approach - about whether there's a better way to do drug discovery - that ultimately it will be faster to market, less expensive, more efficient," says @RecursionPharma CEO on using AI for pharmaceutical development:
Breaking: Recursion and Exscientia have struck one of the biggest M&A deals in AI bio $RXRX and $EXAI have agreed to merge in an all-stock deal, the two companies announced Thursday: endpts.com/breaking-recur…
Building the Neuromap was a unique challenge for our teams, and something that had never been done before. We had to push beyond our normal AI and DS comfort zones to make it happen. I'm super proud of the team delivering here and everyone who got this option over the line!
Announcing the 1st #neuroscience phenomap – “Neuromap” – optioned under our collaboration with @Roche and @Genentech for $30m. To build it, we produced over 1 trillion hiPSC-derived #neuronal cells – one of the largest such datasets – & scaled new genetic perturbation techniques.…
Announcing the 1st #neuroscience phenomap – “Neuromap” – optioned under our collaboration with @Roche and @Genentech for $30m. To build it, we produced over 1 trillion hiPSC-derived #neuronal cells – one of the largest such datasets – & scaled new genetic perturbation techniques.…
United States Trends
- 1. Broncos 54.1K posts
- 2. Bo Nix 15.1K posts
- 3. Geno 15.7K posts
- 4. Sean Payton 3,873 posts
- 5. Kenny Pickett 1,365 posts
- 6. #TNFonPrime 3,655 posts
- 7. Chip Kelly 1,621 posts
- 8. Bradley Beal 2,447 posts
- 9. Jalen Green 4,839 posts
- 10. Pete Carroll 1,308 posts
- 11. Jeanty 6,002 posts
- 12. Troy Franklin 2,278 posts
- 13. Daniel Carlson N/A
- 14. Thursday Night Football 5,792 posts
- 15. #LVvsDEN 3,977 posts
- 16. Brock Bowers 4,414 posts
- 17. #911onABC 25.3K posts
- 18. Al Michaels N/A
- 19. Ty Lue 1,056 posts
- 20. #WickedOneWonderfulNight 4,382 posts
You might like
-
Breanna Hughes
@unbrelievable -
Karl Martin
@KarlTheMartian -
Russell Samuels
@RussSamuels -
minodisk
@minodisk -
Kevin Kliman
@kkliman -
Shohei Takeda
@takedajs -
Anna Rosen
@whatsupanna -
bamadan 🇺🇸
@bamadan91 -
Michelle McBane
@michellemcbane -
Richard Penner
@richardpenner -
Saif Abid
@SaifAbid -
Tarun Sachdeva
@tarunsachdeva
Something went wrong.
Something went wrong.